Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA.

Blood. 2015 Dec 24;126(26):2798-804. doi: 10.1182/blood-2015-06-644336. Epub 2015 Sep 16.

2.

Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.

Yasenchak CA, Tseng WY, Yap M, Rembert D, Patt DA.

Leuk Lymphoma. 2015;56(11):3143-9. doi: 10.3109/10428194.2015.1030639. Epub 2015 May 18.

PMID:
25860233
3.

Response to rituximab in patients with type II cryoglobulinemia.

Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ, Yasenchak CA, Kumar SK, Gertz MA.

Clin Lymphoma Myeloma. 2006 Sep;7(2):140-4.

PMID:
17026826

Supplemental Content

Loading ...
Write to the Help Desk